Browse Studies — Arctuva

Deliver Insights in Hypertrophic Cardiomyopathy and Observational Outcomes in Real World: United States and European Prospective Registry Study

This registry evaluates patient characteristics, real-world treatment patterns, and short- and long-term outcomes in a population of patients in the United Sta…

Obstructive Hypertrophic Cardiomyopathy

Estimated

~$10 – $1,125

Bristol-Myers SquibbNCT05489705

Phase 2

A Global Phase 2b, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy - FORTITUDE-HCM

FORTITUDE-HCM is a global, multicenter, double-blind, parallel-group, placebo-controlled Phase 2b study that will assess the efficacy and safety of ninerafaxst…

Non-obstructive Hypertrophic Cardiomyopathy

Estimated

~$10 – $8,750

Imbria Pharmaceuticals, Inc.NCT07023614

Coronary Flow Reserve in oHCM Patients Before and After 12 Months of Standard-of-care Mavacamten Treatment as Assessed by PET/CT

The goal of this observational study is to measure the effect of mavacamten treatment on blood flow in the heart muscle (myocardium) in patients with obstructi…

Obstructive Hypertrophic Cardiomyopathy

Estimated

~$10 – $1,125

Michael AyersNCT06023186

Real-World Camzyos Patient Reported OutcoMes Through PAtient SurveyS in Hypertrophic CardioMyopathy (COMPASS-HCM): A Prospective Longitudinal Study

This real-world study will assess changes in health status among participants with symptomatic obstructive hypertrophic cardiomyopathy who are treated with mav…

Obstructive Hypertrophic Cardiomyopathy

Estimated

~$10 – $1,125

Bristol-Myers SquibbNCT06551129